Bank of America Spends Big on GLP-1 Drugs

Bank of America faces a growing healthcare cost. The company spends a quarter-billion dollars each year on GLP-1 drugs for its employees. Brian Moynihan, the CEO, shared this large number with investors.

GLP-1 drugs like Ozempic and Wegovy help people with diabetes and weight loss. These drugs are very popular. Their high cost creates a challenge for many companies and health plans.

Employers across the country are seeing this trend. The drugs can cost thousands of dollars for each person every year. This expense adds up fast for large companies.

Bank of America's spending shows the major impact of these drugs on company budgets. As more people use GLP-1s, companies must find ways to manage these rising healthcare costs.

Source: CNBC